In contrast to NSCLC, especially Adenocarcinoma, wherein discovery of targetable therapy (e.g. for EGFR, ALK1 and ROS1) has resulted in remarkable impact in the therapeutic outcomes, the genetic abnormalities in PSC are largely poorly defined. Here, EGFR is linked to adenocarcinoma.